Core Viewpoint - Investors in Genmab A/S should closely monitor the stock due to significant movements in the options market, particularly the high implied volatility of the Feb. 20, 2026 $12.5 Call option [1] Company Analysis - Genmab is currently rated as Zacks Rank 3 (Hold) in the Medical - Biomedical and Genetics industry, which ranks in the top 34% of the Zacks Industry Rank [3] - Over the past 30 days, three analysts have raised their earnings estimates for the current quarter, resulting in an increase of the Zacks Consensus Estimate from 44 cents per share to 46 cents [3] Options Market Insights - The high implied volatility surrounding Genmab shares indicates that options traders are anticipating a significant price movement, which could suggest an upcoming event that may lead to a substantial rally or sell-off [2][4] - Seasoned options traders often seek out options with high implied volatility to sell premium, aiming to benefit from the decay of the option's value if the underlying stock does not move as much as expected [4]